BCM
RNTX

BIOS Capital Management’s Rein Therapeutics RNTX Stock Holding History

BIOS Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
2,982,375
+1,000,000
+50% +$1.21M 7.44% 4
2026
Q1 		$2.58M Buy
1,982,375
+291,624
+17% +$362K 4.87% 4
2025
Q4 		$1.96M Hold
1,690,751
– – 2.37% 5
2025
Q3 		$1.94M Hold
1,690,751
– – 2.19% 5
2025
Q2 		$2.37M Hold
1,690,751
– – 3.26% 4
2025
Q1 		$2.99M Hold
1,690,751
– – 3.78% 3
2024
Q4 		$3.89M Buy
+1,690,751
New +$5.12M 4.13% 3

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BIOS Capital Management's RNTX Position: Q2 2026 in Review

BIOS Capital Management increased its Rein Therapeutics (RNTX) stake by 50% in Q2 2026, buying an estimated $1.21M and bringing the position to 2,982,375 shares worth $3.1M. The position accounts for 7.44% of the portfolio, ranked #4.

BIOS Capital Management first reported a position in RNTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.89M in Q4 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • BIOS Capital Management held 2,982,375 shares of Rein Therapeutics worth $3.1M as of Q2 2026.
  • BIOS Capital Management bought 1,000,000 Rein Therapeutics shares in Q2 2026, an estimated $1.21M.
  • Rein Therapeutics made up 7.44% of BIOS Capital Management's portfolio in Q2 2026, its #4 holding.
  • BIOS Capital Management first reported a position in Rein Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BIOS Capital Management's Rein Therapeutics position peaked at $3.89M in Q4 2024.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on BIOS Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.